Immunoconjugates is the most prominent nanomedicine platform exploited for the active targeting PS delivery for esophageal cancer, with the anti-HER-2 and anti-EGFR antibodies being the most employed [69,70]. This evidence concerns the gene ERBB2 and esophageal cancer.